NEW YORK – Novellus on Monday said it is working with Tempus to accelerate patient enrollment for its BRAF inhibitor program.
NEW YORK – Novellus on Monday said it is working with Tempus to accelerate patient enrollment for its BRAF inhibitor program.
...and receive Daily News bulletins.
Already have a GenomeWeb or 360Dx account?
Login Now.
Don't have a GenomeWeb or 360Dx account?
Register for Free.